Investors & Media

Nasdaq

Investor Relations

For more information and the latest news about Merus N.V., please visit our Investor Relations section by clicking the button below.

[This section of the website is under construction. You will be temporarily re-routed to Merus’ old website.] 

Investors & Media
Stock information
Nasdaq : MRUS (Common Stock)
$11.70
Change : 0.6 4.88%
Volume : 34,397
Market Cap : 266.185M
Data as of January 23, 2019 @ 04:00 pm EST
(Data provided by Nasdaq. Maximum 15 minutes delayed)
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, Netherlands,… 
Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global… 
Clinical milestones for four lead Biclonics® programs expected in 2019 Cash expected to be… 
Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies Regeneron… 
UTRECHT, The Netherlands, November 8, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
UTRECHT, The Netherlands, September 27, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B.… 
UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
– Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of… 
the company's presence in 2018

Upcoming events

Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events.

All events
Investors & media
Investor

Downloads

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

Code of Business Conduct and Ethics
Merus' Code of Business Conduct and Ethics
April 30, 2018
2017 ANNUAL REPORT (20-F), SEC FILING
Merus' 2017 Annual Report 20-F form, SEC filing. Registration of securities of foreign private issuers pursuant to section 12(b) or (g), filed on April 30, 2018.
January 7, 2019
January Investor Presentation
Merus Corporate Presentation - January 2019
June 15, 2017
Biopharma Dealmakers – Merus Profile
Published article "Battling Cancer with Bispecific Antibodies" in BioPharma Dealmakers, June 2017.